Recommendations for pre-symptomatic genetic testing for hereditary transthyretin amyloidosis in the era of effective therapy: a multicenter Italian consensus

[1]  M. Sabatelli,et al.  Diagnosis and Treatment of Hereditary Transthyretin Amyloidosis (hATTR) Polyneuropathy: Current Perspectives on Improving Patient Care , 2020, Therapeutics and clinical risk management.

[2]  P. Hawkins,et al.  Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy , 2020, Journal of Neurology.

[3]  C. Autore,et al.  Low Sensitivity of Bone Scintigraphy in Detecting Phe64Leu Mutation-Related Transthyretin Cardiac Amyloidosis. , 2019, JACC. Cardiovascular imaging.

[4]  M. Slama,et al.  Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease , 2019, Nature Reviews Neurology.

[5]  C. Lemos,et al.  Twenty Years of a Pre-Symptomatic Testing Protocol for Late-Onset Neurological Diseases in Portugal. , 2019, Acta medica portuguesa.

[6]  M. Emdin,et al.  Accuracy of 99mTc-Hydroxymethylene diphosphonate scintigraphy for diagnosis of transthyretin cardiac amyloidosis , 2019, Journal of Nuclear Cardiology.

[7]  I. Conceição,et al.  Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations* , 2019, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[8]  O. Suhr.  Commentary to Isabel Conceição et al. early diagnosis through targeted follow-up of identified carriers of TTR gene mutations , 2019, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[9]  G. Merlini,et al.  Transthyretin deposition in the eye in the era of effective therapy for hereditary ATTRV30M amyloidosis , 2019, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[10]  Eric J Velazquez,et al.  Guidelines for Performing a Comprehensive Transthoracic Echocardiographic Examination in Adults: Recommendations from the American Society of Echocardiography. , 2019, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[11]  J. Fox,et al.  Cardiac ATTR amyloid nuclear imaging—not all bone scintigraphy radionuclide tracers are created equal , 2018, Journal of Nuclear Cardiology.

[12]  A. Durr,et al.  Reverse pre-symptomatic testing for Huntington disease: double disclosure when 25% at-risk children reveal the genetic status to their parent , 2018, European Journal of Human Genetics.

[13]  D. Adams,et al.  Familial amyloid polyneuropathy , 2017, Current opinion in neurology.

[14]  G. Abbruzzese,et al.  1993–2014: two decades of predictive testing for Huntington's disease at the Medical Genetics Unit of the University of Genoa , 2017, Molecular genetics & genomic medicine.

[15]  P. Ponikowski,et al.  [2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure]. , 2016, Kardiologia polska.

[16]  P. Andersen,et al.  Presymptomatic ALS genetic counseling and testing , 2016, Neurology.

[17]  James C Moon,et al.  Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis , 2016, Circulation.

[18]  M. Russo,et al.  Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area , 2016, Journal of Neurology.

[19]  D. Adams,et al.  Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis , 2016, Current opinion in neurology.

[20]  G. Vita,et al.  TTR-FAP: a single-center experience in Sicily, an Italian endemic area , 2015, Orphanet Journal of Rare Diseases.

[21]  J. Moon,et al.  Differential Myocyte Responses in Patients with Cardiac Transthyretin Amyloidosis and Light-Chain Amyloidosis: A Cardiac MR Imaging Study. , 2015, Radiology.

[22]  F. Salvi,et al.  Cardiac amyloidosis: the great pretender , 2015, Heart Failure Reviews.

[23]  P. Westermark,et al.  Transthyretin-derived amyloidosis: Probably a common cause of lumbar spinal stenosis , 2014, Upsala journal of medical sciences.

[24]  B. Hazenberg,et al.  Bone scintigraphy with 99mtechnetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloidosis , 2014, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[25]  M. Carvalho,et al.  Neurophysiological techniques to detect early small‐fiber dysfunction in transthyretin amyloid polyneuropathy , 2014, Muscle & nerve.

[26]  V. Algalarrondo,et al.  FAP Neuropathy and Emerging Treatments , 2014, Current Neurology and Neuroscience Reports.

[27]  A. Chiò,et al.  Genetic counselling in ALS: facts, uncertainties and clinical suggestions , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[28]  M. Lo Monaco,et al.  TTR-related amyloid neuropathy: clinical, electrophysiological and pathological findings in 15 unrelated patients , 2013, Neurological Sciences.

[29]  A. Feldman.  Commercial Clinical Genetic Sequencing Panels for Evaluating Patients with Familial Disease—Are They Ready for Prime Time? , 2013, Clinical and translational science.

[30]  D. Craufurd,et al.  Recommendations for the Predictive Genetic Test in Huntington's Disease Committee and Working Group 'genetic Testing Counselling' of the European Huntington Disease Network †, ‡ , 2022 .

[31]  J. Lefaucheur,et al.  Neurophysiological markers of small fibre neuropathy in TTR-FAP mutation carriers , 2013, Journal of Neurology.

[32]  H. Skirton,et al.  Quality in genetic counselling for presymptomatic testing — clinical guidelines for practice across the range of genetic conditions , 2012, European Journal of Human Genetics.

[33]  P. García-Pavía,et al.  Role of cardiac scintigraphy with ⁹⁹mTc-DPD in the differentiation of cardiac amyloidosis subtype. , 2012, Revista espanola de cardiologia.

[34]  V. Planté-Bordeneuve,et al.  Familial amyloid polyneuropathy , 2019, Journal of the Neurological Sciences.

[35]  C. Briani,et al.  Variable presentations of TTR‐related familial amyloid polyneuropathy in seventeen patients , 2011, Journal of the peripheral nervous system : JPNS.

[36]  G. Vita,et al.  Psychosocial impact of presymptomatic genetic testing for transthyretin amyloidotic polyneuropathy , 2009, Neuromuscular Disorders.

[37]  P. Low,et al.  Patterns of neuropathy and autonomic failure in patients with amyloidosis. , 2008, Mayo Clinic proceedings.

[38]  M. Benson,et al.  The molecular biology and clinical features of amyloid neuropathy , 2007, Muscle & nerve.

[39]  A. Sousa,et al.  Familial ATTR amyloidosis: microalbuminuria as a predictor of symptomatic disease and clinical nephropathy. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[40]  M. Saraiva,et al.  Amyloid fibril protein in familial amyloidotic polyneuropathy, Portuguese type. Definition of molecular abnormality in transthyretin (prealbumin). , 1984, The Journal of clinical investigation.

[41]  Volkmar Falk,et al.  2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. , 2016, Revista espanola de cardiologia.

[42]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..